## PRESS RELEASE





## OPSENS TO HOST FIRST QUARTER FISCAL YEAR 2021 FINANCIAL RESULTS CONFERENCE CALL ON WEDNESDAY, JANUARY 13, 2021

## Conference call to be conducted at 11:00 am ET

Quebec City, Quebec, January 6, 2021 – OpSens Inc. ("OpSens" or the "Company") (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical technology, will report financial results for its first quarter of fiscal year 2021, ended November 30, 2020, on Wednesday, January 13, 2021 before the open of the market. The Company has scheduled a conference call that same day, Wednesday, January 13, 2021 at 11:00 am ET, to review the results.

Interested parties can access the conference call by dialing (877) 270-2148 or (412) 902-6510 or can listen via a live Internet webcast, which is available in the Investors section of the Company's website at <a href="https://opsens.com/investors/">https://opsens.com/investors/</a> or at <a href="https://www.webcaster4.com/Webcast/Page/2512/39370">https://opsens.com/investors/</a> or at <a href="https://www.webcaster4.com/Webcast/Page/2512/39370">https://www.webcaster4.com/Webcast/Page/2512/39370</a>.

A teleconference replay of the call will be available for three days at (877) 344-7529 or (412) 317-0088, confirmation # 10150894. A webcast replay will be available in the Investors section of the Company's website at <a href="https://opsens.com/investors/">https://opsens.com/investors/</a> or at <a href="https://www.webcaster4.com/Webcast/Page/2512/39370">https://www.webcaster4.com/Webcast/Page/2512/39370</a>.

## About OpSens Inc. (www.OpSens.com or www.OpSensmedical.com)

OpSens focuses mainly on coronary artery stenosis measurement in interventional cardiology. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 100,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada.

OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.

For further information, please contact: Louis Laflamme, CPA, CA, Chief Executive Officer, 418.781.0333

Robin Villeneuve, CPA, CA Chief Financial Officer, 418.781.0333